Eli Lilly’s best-selling diabetes drug Mounjaro lowered the risk of heart attacks and stroke in a late-stage trial, the ...

Shares of Eli Lilly And Co. (LLY) and Novo Nordisk (NVO) jumped on Friday following reports that the Trump administration is ...

Eli Lilly (NYSE:LLY) stock rose 1.3% and Novo Nordisk (NYSE:NVO) shares jumped 2% Friday morning after The Washington Post ...

The Washington Post reported the CMS is considering a plan that could allow Medicare plans to pay for the drugs.

Shares in Novo Nordisk fell as much as 6% on Friday before recovering some ground later in the session, extending recent ...

Investors and analysts say they expect Eli Lilly to report stronger quarterly sales and profit next week than Danish rival ...

Novo Nordisk stock plunges 30% after forecast cut, CEO shakeup, and rising competition hit investor confidence.

Yahoo Finance anchor Julie Hyman tracks Friday's top moving stocks and biggest market stories in this Market Minute. Big Bank ...

Eli Lilly stock slips after Novo Nordisk trims 2025 forecast; Jaypirca meets endpoint in CLL trial against J&J's Imbruvica, ...

The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.

This peer was Novo Nordisk, which like Eli Lilly sells a popular drug approved specifically for obesity. Eli Lilly's recent popularity is due in no small measure to its plunge into the highly ...

Eli Lilly is set to report Q2 2025 earnings on August 7, with consensus expecting $14.4 billion in revenue and $5.56 EPS, up 30-42% YoY. Learn more on LLY stock here.